{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:08:57Z","timestamp":1789186137200,"version":"build-2803163510"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7499-26","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:11:19Z","timestamp":1788819079000},"source":"Crossref","is-referenced-by-count":0,"title":["Efgartigimod and Steroid Pulse Therapy as an Early Fast-acting Treatment Strategy for Anti-MUSK Myasthenic Crisis"],"prefix":"10.2169","author":[{"given":"Joe","family":"Senda","sequence":"first","affiliation":[{"name":"Department of Neurology and Rehabilitation, Komaki City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Komaki City Hospital, Japan"},{"name":"Department of Cardiology, Komaki City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikuko","family":"Kamiya-Goto","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Komaki City Hospital, Japan"},{"name":"Department of Emergency and Critical Care Medicine, Nagoya University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Amakusa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Fukami","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Komaki City Hospital, Japan"},{"name":"Department of Cardiology, Komaki City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Komaki City Hospital, Japan"},{"name":"Department of Cardiology, Komaki City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomized, placebo-controlled, phase 3 trial. Lancet Neurol 20: 526-536, 2021.","DOI":"10.1212\/WNL.96.15_supplement.4520"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord 14: 1-7, 2021.","DOI":"10.1177\/1756286421997381"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Arsura E, G Brunner NG, Namba T, et al. High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 42: 1149-1153, 1085.","DOI":"10.1001\/archneur.1985.04060110031011"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Bever CT Jr, Aquino AV, Penn AS, et al. Prognosis of ocular myasthenia. Ann Neurol 14: 516-519, 1983.","DOI":"10.1002\/ana.410140504"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for the management of myasthenia gravis: 2020 update. Neurology 96: 114-122, 2021.","DOI":"10.1212\/WNL.0000000000011124"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Uzawa A, Suzuki S, Kuwabara S, et al. Effectiveness of early cycles of fast-acting treatment in generalized myasthenia gravis. J Neurol Neurosurg Psychiatry 94: 467-473, 2023.","DOI":"10.1136\/jnnp-2022-330519"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Bril V, Howard JF Jr, Karam C, et al. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study. Eur J Neurol 31: e16098, 2024.","DOI":"10.1111\/ene.16098"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Luo S, Jiang Q, Zeng W, et al. Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China. Ann Clin Transl Neurol 11: 2212-2221, 2024.","DOI":"10.1002\/acn3.52142"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tanaka K, Yoshikawa M, Inoue Y, et al. Efgartigimod successfully ameliorated acute exacerbation of myasthenia gravis with anti-muscle-specific kinase antibody. Intern Med 64: 925-929, 2025.","DOI":"10.2169\/internalmedicine.3726-24"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gerischer L, Doksani P, Hoffmann S, et al. New and emerging biological therapies for myasthenia gravis: a focused review for clinical decision-making. BioDrugs 39: 185-213, 2025.","DOI":"10.1007\/s40259-024-00701-1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ohara H, Kikutsuji N, Iguchi N, et al. Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report. BMC Neurol 24: 292, 2024.","DOI":"10.1186\/s12883-024-03804-y"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zhang Z, Yang M, Luo T, et al. Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report. Ther Adv Neurol Disord 17: 17562864241254896, 2024.","DOI":"10.1177\/17562864241254895"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sun F, Batra A, Dickson D, et al. Efgartigimod infusion in the treatment regimen for myasthenic crisis: a case report. Muscle Nerve 70: 290-292, 2024.","DOI":"10.1002\/mus.28178"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Omar OA, Diel NJ, Gerner ST, et al. Efgartigimod as rescue medication in a patient with refractory myasthenic crisis. Case Rep Neurol Med 2024: 9455237, 2024.","DOI":"10.1155\/2024\/9455237"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Watanabe K, Ohashi S, Watanabe T, et al. Case report: recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod. Front Neurol 15: 1321058, 2024.","DOI":"10.3389\/fneur.2024.1321058"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Morita Y, Osaki T, Shogase T, et al. Effective efgartigimod treatment for severe thymoma-associated myasthenia gravis experiencing myasthenic crisis: a case report. Neurol Clin Neurosci 12: 312-315, 2024.","DOI":"10.1111\/ncn3.12813"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Roper J, Fleming ME, Long B, Koyfman A. Myasthenia gravis and crisis: evaluation and management in the emergency department. J Emerg Med 53: 843-853, 2017.","DOI":"10.1016\/j.jemermed.2017.06.009"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kawaguchi N, Tsuda K, Tanaka N, et al. Myasthenia gravis disease burden and its impact on satisfaction with life: a qualitative survey of patients\u2019 perspectives in Japan. Neurol Ther 13: 1099-1113, 2024.","DOI":"10.1007\/s40120-024-00617-6"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Morsch M, Reddel SW, Ghazanfari N, et al. Pyridostigmine, but not 3,4-diaminopyridine, exacerbates ACh receptor loss and myasthenia induced by muscle-specific kinase autoantibodies in mice. J Physiol 591: 2747-2762, 2013.","DOI":"10.1113\/jphysiol.2013.251827"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Evoli A, Alboini PE, Damato V, et al. Diagnosis and therapy of MuSK-antibody-positive myasthenia gravis. Ann N Y Acad Sci 1412: 82-89, 2018.","DOI":"10.1111\/nyas.13518"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hatanaka Y, Hemmi S, Morgan MB, et al. Non-responsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology 65: 1508-1509, 2005.","DOI":"10.1212\/01.wnl.0000183145.91579.74"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7499-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:29:35Z","timestamp":1789183775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7499-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":21,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7499-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7499-26"}}